Ospedale S. Eugenio, ASL Roma 2

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Acute lymphoblastic leukaemia3 trials
• Acute myeloid leukaemia2 trials
• Myelodysplastic syndromes2 trials
• Chronic lymphocytic leukaemia1 trial
• Chronic myeloid leukaemia1 trial
• Myeloproliferative neoplasms1 trial

Phase

• Phase 25 trials
• Phase 34 trials
• Phase 41 trial

Status

• Active, not recruiting4 trials
• Recruiting4 trials
• Completed2 trials

Lead sponsor

• Gruppo Italiano Malattie EMatologiche dell'Adulto5 trials
• Fondazione Gimema Franco Mandelli Onlus2 trials
• Associazione Qol-One1 trial
• Fondazione G.I.M.Em.A Franco Mandelli Ets1 trial
• Geron Corporation1 trial

Running trials

• Recruiting

  Eltrombopag for the treatment of thrombocytopenia due to low - and intermediate risk myelodysplastic syndromes.

  NCT02912208· Phase 2· Associazione Qol-One· Source

• Active, not recruiting

  Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL

  NCT05478512· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Active, not recruiting

  Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients suffering from Acute Myeloid Leukemia with NPM1 mutation.

  NCT04867928· Phase 2· Fondazione G.I.M.Em.A Franco Mandelli Ets· Source

• Active, not recruiting

  Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

  NCT04722848· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Active, not recruiting

  A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

  NCT04576156· Phase 3· Geron Corporation· Source

• Recruiting

  Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)

  NCT04184505· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Recruiting

  Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

  NCT04168502· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

• Active, not recruiting

  Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

  NCT03610438· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myelodysplastic syndromes2 recruiting
• Acute myeloid leukaemia1 recruiting
• Chronic lymphocytic leukaemia1 recruiting

Closed trials

• Completed

  The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in patients: MRD positive (persistent or relapsed), patients after haematological and extra-haematological relapse and patients who do not have never achieved remission after any previous treatment.

  NCT04475731· Phase 2· Fondazione Gimema Franco Mandelli Onlus· Source

• Completed

  Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing a drug called Nilotinib versus another called Imatinib with switch to Nilotinib in absence of optimal response.

  NCT02602314· Phase 4· Fondazione Gimema Franco Mandelli Onlus· Source